Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of a Functional Nanobody Targeting Programmed Cell Death Protein-1 as Immune Checkpoint Inhibitor

Author(s): Mohammad Hosseininejad-Chafi, Zahra Kianmehr, Kamran Pooshang-Bagheri, Fatemeh Kazemi-Lomedasht and Mahdi Behdani*

Volume 29, Issue 29, 2023

Published on: 04 October, 2023

Page: [2336 - 2344] Pages: 9

DOI: 10.2174/0113816128258475230920054122

Price: $65

Abstract

Background: Programmed cell death protein 1 (PD-1) is a membrane receptor that is expressed on the surface of various immune cells, such as T cells, B cells, monocytes, natural killer T cells, and dendritic cells. In cancer, the interaction between PD-1 and its ligand PD-L1 suppresses the activation and function of T lymphocytes, leading to the impairment and apoptosis of tumor-specific T cells. This mechanism allows cancer cells to evade the immune response and promotes tumor progression.

Methods: Recombinant PD-1 protein was produced and used to immunize a camel. A nanobody library was generated from the camel’s peripheral blood lymphocytes and screened for PD-1 binding. A specific nanobody (3PD9) was selected and characterized by affinity measurement, western blotting, and flow cytometry analysis. The ability of the selected nanobody to block the inhibitory signal of PD-1 in peripheral blood mononuclear cells (PBMCs) was evaluated by measuring the level of interleukin-2 (IL-2).

Results: The selected nanobody showed high specificity and affinity for human PD-1. Western blot and flow cytometry analysis confirmed that 3PD9 could recognize and bind to human PD-1 on the cell surface. It was demonstrated that the level of IL-2 was significantly increased in PBMCs treated with 3PD9 compared to the control group, indicating that the nanobody could enhance the T cell response by disrupting the PD-1/PD-L1 interaction.

Conclusion: The results suggested that the anti-PD-1 nanobody could be a promising candidate for cancer immunotherapy.

« Previous Next »
[1]
Ji M, Liu Y, Li Q, et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med 2015; 13(1): 5.
[http://dx.doi.org/10.1186/s12967-014-0373-0] [PMID: 25592115]
[2]
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26(1): 677-704.
[http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331] [PMID: 18173375]
[3]
Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012; 209(6): 1201-17.
[http://dx.doi.org/10.1084/jem.20112741] [PMID: 22641383]
[4]
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11(11): 3887-95.
[http://dx.doi.org/10.1002/j.1460-2075.1992.tb05481.x] [PMID: 1396582]
[5]
Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 1994; 23(3): 704-6.
[http://dx.doi.org/10.1006/geno.1994.1562] [PMID: 7851902]
[6]
Terawaki S, Chikuma S, Shibayama S, et al. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 2011; 186(5): 2772-9.
[http://dx.doi.org/10.4049/jimmunol.1003208] [PMID: 21263073]
[7]
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192(7): 1027-34.
[http://dx.doi.org/10.1084/jem.192.7.1027] [PMID: 11015443]
[8]
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci 2010; 107(17): 7875-80.
[http://dx.doi.org/10.1073/pnas.1003345107] [PMID: 20385810]
[9]
Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013; 139(3): 667-76.
[http://dx.doi.org/10.1007/s10549-013-2581-3] [PMID: 23756627]
[10]
Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348(6230): 56-61.
[http://dx.doi.org/10.1126/science.aaa8172] [PMID: 25838373]
[11]
Sun S, Fei X, Mao Y, et al. PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother 2014; 63(4): 395-406.
[http://dx.doi.org/10.1007/s00262-014-1519-x] [PMID: 24514954]
[12]
Ljunggren HG, Jonsson R. Hِglund P. Seminal immunologic discoveries with direct clinical implications: The 2018 nobel prize in physiology or medicine honours discoveries in cancer immunotherapy. Scand J Immunol 2018; 88e12731
[13]
Messenheimer DJ, Jensen SM, Afentoulis ME, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with Anti-OX40. Clin Cancer Res 2017; 23(20): 6165-77.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-2677] [PMID: 28855348]
[14]
Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017; 24(1): 26.
[http://dx.doi.org/10.1186/s12929-017-0329-9] [PMID: 28376884]
[15]
Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: A review. JAMA Oncol 2016; 2(9): 1217-22.
[http://dx.doi.org/10.1001/jamaoncol.2016.0639] [PMID: 27310809]
[16]
Conrath KE, Lauwereys M, Galleni M, et al. β-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother 2001; 45(10): 2807-12.
[http://dx.doi.org/10.1128/AAC.45.10.2807-2812.2001] [PMID: 11557473]
[17]
Jovčevska I, Zupanec N, Kočevar N, et al. TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers. PLoS One 2014; 9(11): e113688.
[http://dx.doi.org/10.1371/journal.pone.0113688] [PMID: 25419715]
[18]
De Meyer T, Eeckhout D, De Rycke R, De Buck S, Muyldermans S, Depicker A. Generation of VHH antibodies against the arabidopsis thaliana seed storage proteins. Plant Mol Biol 2014; 84(1-2): 83-93.
[http://dx.doi.org/10.1007/s11103-013-0118-0] [PMID: 23963604]
[19]
Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 1987; 100(1-2): 173-9.
[http://dx.doi.org/10.1016/0022-1759(87)90187-6] [PMID: 2439600]
[20]
Kozakov D, Hall DR, Xia B, et al. The ClusPro web server for protein-protein docking. Nat Protoc 2017; 12(2): 255-78.
[http://dx.doi.org/10.1038/nprot.2016.169] [PMID: 28079879]
[21]
Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera?A visualization system for exploratory research and analysis. J Comput Chem 2004; 25(13): 1605-12.
[http://dx.doi.org/10.1002/jcc.20084] [PMID: 15264254]
[22]
Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng Des Sel 1995; 8(2): 127-34.
[http://dx.doi.org/10.1093/protein/8.2.127] [PMID: 7630882]
[23]
Zare H, Rajabibazl M, Rasooli I, et al. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells. Int J Biol Markers 2014; 29(2): 169-79.
[http://dx.doi.org/10.5301/jbm.5000063] [PMID: 24425321]
[24]
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8(8): 793-800.
[http://dx.doi.org/10.1038/nm730] [PMID: 12091876]
[25]
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443-54.
[http://dx.doi.org/10.1056/NEJMoa1200690] [PMID: 22658127]
[26]
Filpula D. Antibody engineering and modification technologies. Biomol Eng 2007; 24(2): 201-15.
[http://dx.doi.org/10.1016/j.bioeng.2007.03.004] [PMID: 17466589]
[27]
Rahbarizadeh F, Rasaee MJ, Forouzandeh Moghadam M, Allameh AA, Sadroddiny E. Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin. Hybrid Hybridomics 2004; 23(3): 151-9.
[http://dx.doi.org/10.1089/1536859041224334] [PMID: 15312305]
[28]
Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380(4): 335-46.
[http://dx.doi.org/10.1056/NEJMoa1806311] [PMID: 30625070]
[29]
Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs 2020; 34(1): 11-26.
[http://dx.doi.org/10.1007/s40259-019-00392-z]
[30]
Wen B, Zhao L, Wang Y, et al. Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1). Prep Biochem Biotechnol 2020; 50(3): 252-9.
[http://dx.doi.org/10.1080/10826068.2019.1692217] [PMID: 31799894]
[31]
Xian Z, Ma L, Zhu M, et al. Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy. Biochem Biophys Res Commun 2019; 519(2): 267-73.
[http://dx.doi.org/10.1016/j.bbrc.2019.08.160] [PMID: 31495493]
[32]
Silva-Pilipich N, Martisova E, Ballesteros-Briones MC, et al. Long-term systemic expression of a novel PD-1 blocking nanobody from an AAV vector provides antitumor activity without toxicity. Biomedicines 2020; 8(12): 562.
[http://dx.doi.org/10.3390/biomedicines8120562] [PMID: 33276580]
[33]
Wang X, Li F, Qiu W, et al. SYNBIP: Synthetic binding proteins for research, diagnosis and therapy. Nucleic Acids Res 2022; 50(D1): D560-70.
[http://dx.doi.org/10.1093/nar/gkab926] [PMID: 34664670]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy